Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells
Autor: | Janet A. Houghton, David A. Adkins, Peter J. Houghton, Atiqur Rahman |
---|---|
Rok vydání: | 1991 |
Předmět: |
Cancer Research
medicine.medical_specialty Cell Survival Leucovorin Alpha interferon Pharmacology Adenocarcinoma Thymidylate synthase law.invention Folic Acid law Internal medicine medicine Tumor Cells Cultured Cytotoxic T cell Cytotoxicity Interferon alfa biology business.industry Drug Synergism Thymidylate Synthase Recombinant Proteins Endocrinology Fluorouracil Cell culture Colonic Neoplasms Interferon Type I biology.protein Recombinant DNA Quinazolines business medicine.drug |
Zdroj: | Cancer communications. 3(7) |
ISSN: | 0955-3541 |
Popis: | Recombinant human interferon-alpha 2a (rIFN-alpha 2a; 500 or 5,000 IU/mL) or [6RS] leucovorin ([6RS]LV; 1 microM) each potentiated the cytotoxic activity of 5-fluorouracil (FUra) by 2.6- to 3.2-fold during 72 hr exposures in two human colon adenocarcinoma cell lines (GC3/c1; VRC5/c1). When all three agents were combined, FUra cytotoxicity was further potentiated by 3.2- to 4.3-fold (total 10- to 14-fold). Potentiation of FUra cytotoxicity occurred at clinically achieveable concentrations of rIFN-alpha 2a and [6RS]LV. Effects were reversed by dThd (20 microM), although the activity of CB3717, a quinazoline-based, specific inhibitor of thymidylate synthase, was not potentiated by rIFN-alpha 2a. Data suggest the requirement of a 5-fluoropyrimidine for biochemical modulation and interaction at the level of thymidylate synthase or DNA. |
Databáze: | OpenAIRE |
Externí odkaz: |